搜尋結果
Overview. The Department of Cardiology was established in 1955 as the internal medicine division of the “Heart Institute Japan affiliated with Tokyo Women's Medical University”, and has been playing a leading role as a pioneer of cardiovascular clinical care in Japan. We have about 76,000 patients in outpatients division and 29,000 ...
Tokyo Women’s Medical University has developed from Tokyo Women’s Medical School and has produced many female physicians who have contributed to our society. Tokyo Women’s Medical University School of Medicine was established in 1950. Tokyo Women’s Medical College was established in 1952.Then, in 1998, the School of Nursing was added.
Yayoi Yoshioka. In 1900, I founded Tokyo Women’s Medical School, the predecessor of Tokyo Women’s Medical University, with the purpose of improving the social position of women, who had very little status at that time. For women to improve their status, they needed to attain financial independence. As a doctor myself, it was my belief that ...
1999: Doctoral Degree (Ph. D.), Graduate School of Medicine, the University of Tokyo 1995-1999: Medical Staff, Cardiovascular Medicine, the University of Tokyo Hospital 1994-1995: Medical Staff, Cardiovascular Medicine, JR Tokyo General Hospital 1993-1994
In order to nurture medical professionals who can promote research in medical sciences and make further benecial contributions to medical sciences and society, we have established the Graduate School of Medical Science (usually a 4-year doctoral course and a 3-year course for exceptional cases).The Ph.D. degree is given to students who have ...
ダビンチ. 手術支援ロボット. 「ダビンチ」 年間約400件、 累計2,000件以上の実績. 腎移植手術は. 年間100例以上実施. 腎移植専門医による. 高度専門医療. 腎泌尿器腫瘍. 患者さんの負担を考慮した. 手術方法. 状態を見極め最善のアプローチを. 目指すがん治療. 優れた人材育成. 世界各国から訪れる医療スタッフ. 充実の研修・フェロープログラムで. 優れた人材を育成. 泌尿器疾患. 専門分野に特化した. 泌尿器科外来. 前立腺腫瘍外来、女性排尿外来、 尿路結石外来など. TOPICS. 手術待機期間について（2024年5月現在) 東京女子医科大学 泌尿器科 医局説明会 開催のご案内. 手術支援ロボット（ダビンチ）を使用する手術が新たに5件 保険適用となりました.
ヒトiPS細胞の大量培養技術開発を基盤としたヒト心筋組織構築と医療応用開発. ヒト多能性幹細胞は、再生医療、創薬・疾患研究における有望なヒト細胞ソースとして世界的に活用が進められています。 一方で、その実用化および研究開発の加速には、安定的な目的細胞の量産化技術が不可欠です。 本研究所では、培養容積当たりの細胞密度を最も高く設定可能である3次元浮遊 撹拌懸濁培養技術に着目し、エイブル株式会社との共同研究によって独自の撹拌翼を開発し、低シェアストレス撹拌によるヒトiPS細胞由来疑集塊の高密度大量培養に成功しました。
